Effects of nifurtimox: A Synthesis of Findings from 13 Studies

  1. Home
  2. Effects of nifurtimox
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of nifurtimox: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of nifurtimox: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

The effects of nifurtimox have been investigated in several studies, including 8 , 3 , and 5 . These studies found that nifurtimox is used as a treatment for Chagas disease and its effects are associated with influencing the metabolism of DNA, RNA, and proteins in the parasite. Specifically, nifurtimox has been shown to damage the parasite's DNA, thereby inhibiting its replication and repair. Furthermore, 11 indicates that lychnopholide encapsulated in polylactide nanocapsules is effective in mice infected with a strain of Trypanosoma cruzi resistant to benznidazole and nifurtimox. This suggests that it may be effective in treating Chagas disease through a different mechanism than nifurtimox. On the other hand, 10 indicates the possibility of enhancing the therapeutic effect of Chagas disease by combining benznidazole with newly developed pyrrolopyrimidine compounds. This result is expected to lead to the development of Chagas disease treatments other than nifurtimox.

Benefits and risks

Benefits summary

Nifurtimox has been shown to be effective in treating Chagas disease. Nifurtimox is expected to suppress the growth of parasites by affecting the metabolism of DNA, RNA, and proteins in the parasites.

Risks summary

Nifurtimox can cause side effects such as loss of appetite, weight loss, nausea, vomiting, nervous excitement, insomnia, depression, seizures, dizziness, headache, drowsiness, myalgia, arthralgia, loss of balance, disorientation, forgetfulness, paresthesia, weakness, acoustic phenomena, peripheral neuropathy, gastralgia, mucosal edema, hepatic intolerance, skin manifestations, and intolerance to alcohol. Nifurtimox has also been suggested to affect the reproductive organs.

Comparison of studies

Commonalities of studies

These studies suggest that nifurtimox may be effective in treating Chagas disease. These studies indicate that nifurtimox may affect the metabolism of DNA, RNA, and proteins in parasites and suppress the growth of parasites. Additionally, these studies indicate that nifurtimox may cause side effects. These studies show that nifurtimox may be beneficial in treating Chagas disease, but the risk of side effects needs to be considered.

Differences in studies

These studies show different results regarding the specific mechanisms of action of nifurtimox. For example, the study in 8 indicates that nifurtimox directly inhibits DNA synthesis, whereas the study in 11 indicates that lychnopholide acts inside Trypanosoma cruzi cells. These research results suggest that the mechanism of action of nifurtimox is complex and requires further research.

Consistency and inconsistencies of results

These studies suggest that nifurtimox may be effective in treating Chagas disease, but its mechanism of action and side effects are not yet fully understood. These studies suggest that the mechanism of action of nifurtimox is complex and requires further research.

Precautions for real-life application

Nifurtimox may be effective in treating Chagas disease, but the risk of side effects must be considered. If you are considering using nifurtimox, it is important to consult your doctor and use it as directed. Also, nifurtimox is not recommended for use during pregnancy or breastfeeding. Nifurtimox should be used with caution if you have other conditions, such as heart disease or liver disease. Nifurtimox should be avoided in combination with alcohol.

Limitations of current research

These studies are all relatively small and their results should be generalized with caution. Additionally, these studies have not adequately investigated the long-term effects of nifurtimox or its effects on different ethnic groups or age groups. Nifurtimox is promising as a treatment for Chagas disease, but further research is needed.

Future research directions

Future research needs to investigate the mechanism of action of nifurtimox in more detail. It is also necessary to investigate the long-term effects of nifurtimox and its effects on different ethnic groups and age groups. Furthermore, it is necessary to investigate whether the therapeutic effect can be enhanced by combining nifurtimox with other therapies.

Conclusion

Nifurtimox may be effective in treating Chagas disease, but the risk of side effects must be considered. Future research needs to investigate the mechanism of action and safety of nifurtimox in more detail. Chagas disease is a serious disease and early treatment is important. If you experience any symptoms of Chagas disease, consult a doctor immediately.

Literature analysis of 13 papers
Positive Content
10
Neutral Content
0
Negative Content
3
Article Type
1
0
0
1
12
1.

A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.

Author: HugBruce, AbbasRichat, LeisterCathie, BurnsJaime, SonnichsenDaryl

ErbB2-positive breast cancer treatment
Cardiac repolarization effects

Neratinib, an ErbB inhibitor, showed no significant effects on cardiac repolarization at therapeutic and supratherapeutic concentrations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Toxic and therapeutic effects of Nifurtimox and Benznidazol on Trypanosoma cruzi ex vivo infection of human placental chorionic villi explants.

Author: RojoGemma, CastilloChristian, DuasoJuan, LiempiAna, DroguettDaniel, GalantiNorbel, MayaJuan Diego, López-MuñozRodrigo, KemmerlingUlrike

Chagas disease treatment
Tissue damage

This study evaluated the toxic and therapeutic effects of nifurtimox (Nfx) and benznidazole (Bnz) on human placental chorionic villi explants infected with Trypanosoma cruzi. Bnz was found to be less toxic than Nfx and effectively prevented parasite-induced tissue damage.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to Nifurtimox-induced cardiac effects.

Author: MeccaMaría Montalto de, BartelLaura C, CastroCarmen Rodríguez de, CastroJosé A

Treatment for Chagas disease
Cardiotoxic effects

This study compared the cardiotoxicity of benznidazole (Bz) and nifurtimox (Nfx) in rats. Bz did not show observable cardiac effects, unlike Nfx, suggesting Bz may pose a lesser risk to heart function in Chagas disease patients.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Effects of buthionine sulfoximine nifurtimox and benznidazole upon trypanothione and metallothionein proteins in Trypanosoma cruzi.

Author: MayaJuan Diego, RodríguezAndrés, PinoLaura, PabónAdriana, FerreiraJorge, PavaniMario, RepettoYolanda, MorelloAntonio

Chagas' disease treatment

This study investigates the presence and function of metallothionein in Trypanosoma cruzi, a parasite that causes Chagas' disease. Metallothionein levels were found to vary between parasite strains and growth phases. Nifurtimox and benznidazole, drugs used to treat Chagas' disease, were shown to decrease metallothionein activity by 70%. The study further examines the potential role of metallothionein-like proteins in drug resistance.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Effects of nifurtimox or benznidazole administration on rat testes: ultrastructural observations and biochemical studies.

Author: BernacchiA S, de CastroC R, de ToranzoE G, CastroJ A

Chagas' disease treatment
Spermatid alterations
Spermatozoa alterations
Testicular toxicity

Nifurtimox and benznidazole caused ultrastructural and biochemical alterations in rat testes. The study showed that nifurtimox had a significant impact on testicular cells, while benznidazole had a lesser effect.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

8.

[Effects of nifurtimox, benznidazole, and beta-lapachone on the metabolism of DNA, RNA and proteins in Trypanosoma cruzi].

Author: GoijmanS G, StoppaniA O

DNA repair
Trypanostatic action

Nifurtimox and benznidazole inhibited DNA, RNA, and protein turnover in T. cruzi epimastigotes. Nifurtimox and beta-lapachone primarily affected DNA stability, while benznidazole had more widespread effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : Spanish

10.

Short-course combination treatment for experimental chronic Chagas disease.

Author: GonzálezSilvia, WallRichard J, ThomasJohn, BraillardStephanie, BrunoriGino, Camino DíazIsabel, CantizaniJuan, CarvalhoSandra, Castañeda CasadoPablo, ChatelainEric, CotilloIgnacio, FiandorJose M, FranciscoAmanda Fortes, GrimsditchDavid, KeenanMartine, KellyJohn M, KesslerAlbane, LuiseChiara, LyonJon J, MacLeanLorna, MarcoMaria, MartinJ Julio, Martinez MartinezMaria S, PatersonChristy, ReadKevin D, Santos-VillarejoAngel, ZuccottoFabio, WyllieSusan, MilesTim J, De RyckerManu

Rapid parasite clearance

This study describes a pyrrolopyrimidine series that shows potential for treating Chagas disease. The combination of a lead compound from this series with benznidazole effectively cleared parasites in vitro and in vivo.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.